Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) major shareholder Ra Capital Management, Llc unloaded 331,396 shares of the company’s stock on the open market in a transaction dated Monday, August 25th. The shares were sold at an average price of $10.96, for a total value of $3,632,100.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Several analysts have recently commented on the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, August 21st. They now have a $10.00 price target on the stock, up previously from $4.00. Separately, analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, August 18th. They now have a $17.00 price target on the stock, up previously from $6.00. Finally, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Achillion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $9.50.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) traded down 2.55% on Wednesday, hitting $11.45. The stock had a trading volume of 13,542,610 shares. Achillion Pharmaceuticals has a 1-year low of $2.26 and a 1-year high of $12.06. The stock’s 50-day moving average is $7.9 and its 200-day moving average is $5.00. The company’s market cap is $1.120 billion. Achillion Pharmaceuticals also was the recipient of unusually large options trading on Monday. Stock traders purchased 8,149 call options on the stock. This represents an increase of approximately 633% compared to the typical volume of 1,112 call options.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings data on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.